X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (538) 538
Book Review (151) 151
Publication (53) 53
Conference Proceeding (25) 25
Book Chapter (7) 7
Newspaper Article (7) 7
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (417) 417
humans (401) 401
oncology (267) 267
female (193) 193
male (175) 175
cancer (157) 157
middle aged (157) 157
aged (138) 138
lung cancer (129) 129
lung neoplasms - pathology (114) 114
false positive reactions (107) 107
adult (106) 106
chemotherapy (103) 103
respiratory system (98) 98
cell lung-cancer (85) 85
carcinoma, non-small-cell lung - pathology (83) 83
crizotinib (75) 75
lung cancer, non-small cell (73) 73
research (72) 72
lung neoplasms - drug therapy (71) 71
care and treatment (70) 70
carcinoma, non-small-cell lung - drug therapy (69) 69
mutation (67) 67
animals (65) 65
metastasis (65) 65
aged, 80 and over (64) 64
lung neoplasms - genetics (60) 60
tumors (60) 60
sensitivity and specificity (59) 59
lung neoplasms - diagnostic imaging (58) 58
antineoplastic agents - therapeutic use (57) 57
prognosis (57) 57
non-small cell lung cancer (55) 55
analysis (53) 53
neoplasm staging (53) 53
carcinoma, non-small-cell lung - genetics (52) 52
cell line, tumor (46) 46
health aspects (46) 46
pharmacology & pharmacy (46) 46
protein kinase inhibitors - therapeutic use (46) 46
surgery (45) 45
survival (45) 45
tomography, x-ray computed (45) 45
nsclc (43) 43
open-label (41) 41
carcinoma, non-small-cell lung - diagnostic imaging (40) 40
false negative reactions (40) 40
apoptosis (39) 39
article (39) 39
treatment outcome (39) 39
cancer therapies (38) 38
cell biology (38) 38
genetic aspects (38) 38
diagnosis (37) 37
medicine & public health (37) 37
retrospective studies (37) 37
gene expression (36) 36
expression (35) 35
lung neoplasms - diagnosis (35) 35
lung neoplasms - surgery (34) 34
lung-cancer (34) 34
patients (34) 34
proteins (34) 34
immunohistochemistry (33) 33
hematology, oncology and palliative medicine (32) 32
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (32) 32
signal transduction (32) 32
biochemistry & molecular biology (31) 31
carcinoma, non-small-cell lung - surgery (31) 31
fluorodeoxyglucose f18 (31) 31
risk factors (31) 31
chronic myeloid-leukemia (30) 30
development and progression (30) 30
anaplastic lymphoma kinase (29) 29
antineoplastic agents - pharmacology (29) 29
lymphomas (29) 29
positron-emission tomography (29) 29
predictive value of tests (29) 29
breast cancer (28) 28
hematology (28) 28
kinases (28) 28
medicine (28) 28
mice (28) 28
neoplasms - drug therapy (28) 28
review (28) 28
adenocarcinoma (27) 27
alk-positive nsclc (27) 27
biomarkers (27) 27
gefitinib (27) 27
metastases (27) 27
positive breast-cancer (27) 27
tyrosine kinase inhibitors (27) 27
acquired-resistance (26) 26
biopsy (26) 26
leukemia (26) 26
pathology (26) 26
protein kinase inhibitors - pharmacology (26) 26
radiology, nuclear medicine & medical imaging (26) 26
receptor, epidermal growth factor - genetics (26) 26
therapy (26) 26
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lung Cancer, ISSN 0169-5002, 2016, Volume 96, pp. 15 - 18
Journal Article
Annals of Oncology, ISSN 0923-7534, 2014, Volume 25, Issue 2, pp. 415 - 422
Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 01/2019, Volume 127, pp. 103 - 111
In the LUX-Lung clinical trials of afatinib in mutation-positive NSCLC, tolerability-guided dose adjustment reduced the incidence and severity of adverse... 
Non-small-cell lung cancer | EGFR mutation-positive | Real-world study | Afatinib | 1ST-LINE TREATMENT | GEFITINIB | MANAGEMENT | ADENOCARCINOMA | OPEN-LABEL | CELL LUNG-CANCER | ONCOLOGY | SURVIVAL-DATA | RESPIRATORY SYSTEM | EXPERIENCE
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 04/2019, Volume 14, Issue 4, pp. 672 - 682
Introduction: The study objective was to determine the incidence and characteristics of drug-induced interstitial lung disease (ILD) associated with an orally... 
Crizotinib | Interstitial lung disease | Tyrosine kinase inhibitor | Anaplastic lymphoma kinase-positive NSCLC | GEFITINIB | KINASE | CANCER | CHEMOTHERAPY | PROFILE | ONCOLOGY | RESPIRATORY SYSTEM | SURVEILLANCE | MUTATIONS | INHIBITOR | PREDICTIVE FACTORS | ERLOTINIB
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2018, Volume 118, Issue 1, pp. 38 - 42
Journal Article
Journal Article
Acta Pharmacologica Sinica, ISSN 1671-4083, 2015, Volume 36, Issue 3, pp. 375 - 384
Aim: Eukaryotic translation initiation factor 3 subunit A (eIF3a) plays critical roles in regulating the initiation of protein translation, and eIF3a is highly... 
eIF3a | Chemotherapy toxicity | Lung cancer | Platinum-based chemotherapy | Positive selection | Chinese NSCLC patients | Polymorphism | platinum-based chemotherapy | chemotherapy toxicity | MOLECULAR POPULATION-GENETICS | LUNG-CANCER PATIENTS | SIGNATURES | polymorphism | TRANSLATION | LOCUS | CHEMISTRY, MULTIDISCIPLINARY | lung cancer | HUMAN GENOME | NATURAL-SELECTION | PHARMACOLOGY & PHARMACY | positive selection | Haplotypes | Lung Neoplasms - drug therapy | Lung Neoplasms - ethnology | Humans | Middle Aged | Asian Continental Ancestry Group - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Drug-Related Side Effects and Adverse Reactions - genetics | Eukaryotic Initiation Factor-3 - genetics | Female | Odds Ratio | Platinum Compounds - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Pharmacogenetics | Carcinoma, Non-Small-Cell Lung - genetics | Gene Frequency | Risk Factors | Carcinoma, Non-Small-Cell Lung - ethnology | Logistic Models | Treatment Outcome | China - epidemiology | Chi-Square Distribution | Phenotype | Polymorphism, Single Nucleotide | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug-Related Side Effects and Adverse Reactions - diagnosis | Organoplatinum Compounds - adverse effects | Index Medicus | Original
Journal Article
LUNG CANCER, ISSN 0169-5002, 06/2016, Volume 96, pp. 15 - 18
Alectinib is a second generation ALK inhibitor that has significant clinical activity in central nervous system (CNS) metastases in anaplastic lymphoma kinase... 
METASTASES | Radiation necrosis | PSEUDOPROGRESSION | Alectinib | GLIOBLASTOMA | Pseudo-progression | ONCOLOGY | RESPIRATORY SYSTEM | RANO GROUP | DISEASE | CRIZOTINIB | RESPONSE ASSESSMENT CRITERIA | ALK-positive non-small cell lung cancer
Journal Article
by Du, X and Zheng, XL and Wang, PC and Wang, Y
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, ISSN 1940-5901, 2018, Volume 11, Issue 11, pp. 11763 - 11771
Objectives: The aim of this meta-analysis was to systematically evaluate efficacy and safety profiles of crizotinib in patients with ALK-positive NSCLC at... 
CELL LUNG-CANCER | MEDICINE, RESEARCH & EXPERIMENTAL | STANDARD CHEMOTHERAPY | crizotinib | GEFITINIB | NSCLC | ALK-positive | meta-analysis | OPEN-LABEL | ERLOTINIB | 1ST-LINE CRIZOTINIB
Journal Article